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Objective. To assess the impact of PPHN on mortality, morbidity, and behavioural skills. Methods. A retrospective observational
study of 143 newborns with PPHN, over an 11-year period, using objective health-status data from medical records and family
doctors, and subjective health status data from a standardized Child Behaviour Checklist. Results. The majority of patients were
males, treated with inhaled nitric oxide had maladaptation/maldevelopment as pathophysiological mechanism and a gestational
age >37 weeks. In term newborns, types of pathophysiological mechanism (P<. 001) and Oxygen Index (P = .02) were
independent predicting risk factors for PPHN-related mortality. Analysis of preexisting disease and outcome categories in term
newborns showed only a signiﬁcant correlation between the use of iNO and respiratory complaints (P = .03), not conﬁrmed
by multivariate analysis and regression analysis. Conclusions. PPHN is a serious, often fatal condition. The incidence of PPHN in
preterm newborns is high. In term survivors, PPHN had no additional role in morbidity/outcome.
1.Introduction
PPHN is deﬁned as a failure of normal pulmonary vascular
adaptationatorsoonafterbirth,resultinginapersistinghigh
pulmonary vascular resistance such that pulmonary blood
ﬂow is diminished and unoxygenated blood is shunted to
systemic circulation, via a right-to-left shunting through an
open foramen ovale and/or a ductus arteriosus [1]. Potential
risk factors, such as prematurity, dysmaturity, infection,
meconium aspiration syndrome, genetic anomalies, and
structural anomalies, are identiﬁed.
PPHN is a complex clinical syndrome with an estimated
incidence of 1.9 per 1000 live-births (0.4–6.8/1000 live-
births) and a reported mortality rate ranging from 4–33%
[2]. Considering the serious nature and mortality rate of
PPHN, the interest in the outcome of surviving children is
generated. Limited data are available on the long-term out-
comeofneonatessurviving PPHN.Previousstudiesreported
an increased appearance of respiratory tract problems, hear-
ingimpairment,delayedmentalandmotordevelopmentand
behavioural problems [3–6]. However, these studies were
partly hampered by small sample sizes, ranging from 11 to
19 patients, partly dated back to the era before inhaled nitric
oxide as treatment modality for PPHN, or limited to term
neonates (GA ≥ 37 weeks) [4–7].
In this study, we retrospectively describe mortality and
morbidity in neonates presenting with PPHN in tertiary car-
diac and neonatal intensive care unit. Furthermore, we stud-
ied the present health status, including child behaviour
scores,ofthetermsurviving neonatesinthiscohortofPPHN
patients.
2.Patientsand Methods
Between January 1995 and January 2006, 143 patients
diagnosedwithPPHN,conﬁrmedbyechocardiography,were
treated consecutively at our institution that serves as a
tertiary cardiac and neonatal intensive care unit. All patients
were included.2 Pulmonary Medicine
The prenatal, perinatal, and neonatal data of all newborn
were collected from the medical record of the patient. Mater-
nal data as age, preexisting diseases, diseases acquired during
pregnancy, use ofmedication, alcohol-, smoking- and drugs-
habits, and pregnancy-related complications were obtained
by a questionnaire. Patient data, concerning severity and
type of pathophysiology of PPHN were determined. Follow-
up data of term responding survivors, retrieved from the
hospital patient records, as well as the medical records held
by the family doctor, contained information about general
health status, focussed on respiratory and gastrointestinal
tract problems, neurological aspects, such as delayed mental
and motor development, hearing- and vision impairment,
the use of medication and other supportive treatment, as
speech therapy and physiotherapy.
The parents of the surviving patients (n = 92, 64.3%)
received the Child Behaviour Checklist. We used a time in-
terval of 6 weeks to respond. The study was approved by
the Institutional Medical Ethics Committee and informed
consent was obtained from each responding parent.
2.1. Child Behaviour Checklist (CBCL). The CBCL is a stan-
dardized measure of child behaviour, developed by Achen-
bach and normalized for Dutch children by Verhulst et al.
Children between 1.5 and 5 years of age received the CBCL
for 1.5 to 5 years (CBCL/1.5–5) [8]. Children older than
5y e a r sr e c e i v e dt h eC B C Lf o r6t o1 8y e a r s( C B C L / 6 –
18). The test is designed to assess child’s behaviour and
social competency, as reported by their parents, implicating
a subjective parental opinion. The questionnaire included
questionsonsocial issues. Moreoverparents are askedto rate
their child, on a scale of not true to true on many diﬀerent
issues, including academics, inattention, relationships, and
behaviours. In the CBCL/1.5–5 skills are not included.
2.2. Deﬁnition of PPHN. PPHN was deﬁned based on a
combination of clinical and echocardiographical character-
istics. Two parameters were obtained to score the severity
of PPHN, the preductal to postductal diﬀerence in transcu-
taneous oxygen saturation (δ-SO2), and the Oxygen Index
(OI), respectively. The preductal to postductal diﬀerence in
transcutaneous oxygen saturation (δ-SO2) was used to scale
severe PPHN (group 1) and mild-moderate PPHN (group
2). Patients with severe PPHN, presented with profound
cyanosis, associated with continuous right-to-left shunting,
demonstrated by echocardiography (i.e., pulmonary to sys-
temiccirculation),throughapatentductusarteriosus(PDA),
on colour ﬂow Doppler and pulsed wave Doppler, or a
predominant right-to-left shunt through a PDA, associated
with a preductal to postductal diﬀerence in transcutaneous
oxygen saturation (δ-SO2) of 15% or greater, as measured
between a right arm and a leg. In patients with mild-
moderate PPHN, bidirectional shunting through the PDA
was observed by echocardiography, associated with a δ-
SO2 between 5% and 15% [1]. Secondly, the Oxygen Index
(OI) of term newborn children was determined by using
the fractional oxygen index (FIO2) in percentages times the
mean airway pressure in cm H2O, divided by the arterial O2
pressure in kilopascal, all three values retrieved in the worst
stage of the PPHN. An OI of <15 was scored as mild PPHN,
between 15–25 as moderate PPHN, between 25–40 as severe,
and more than 40 as very severe PPHN [9].
2.3. Type of Pathophysiological Mechanism. Hypothetically,
the pathophysiological mechanisms, responsible for PPHN,
are classiﬁed into maladaptation, maldevelopment, and
underdevelopment, as described in the article of Dakshi-
namurti [10]. Maladaptation of the normal developed pul-
monary vasculature through an imbalance of vasoactive
substrates is responsible for the greater part of PPHN and
originates often from sepsis, pneumonia, meconium aspira-
tion syndrome, or asphyxia. Abnormal development of the
pulmonary vasculature (maldevelopment) is mainly idio-
pathic but sometimes associated with chronic fetal hypoxia,
fetal anaemia, or premature closure of the ductus arteriosus.
Lunghypoplasia with underdevelopment of pulmonary vas-
culature (underdevelopment)originates from several causes,
however congenital diaphragmatic hernia or oligohydram-
nios form the majority of these causes. The discrimination
of maladaptation and maldevelopment, however, is diﬃcult
or even impossible without histological specimen. Therefore
patients were classiﬁed into maladaptation/maldevelopment
(group 1) and underdevelopment (group 2), based on
medical history, clinical course, and additional imaging, as
chest X-ray.
2.4.TreatmentStrategiesinPPHN. TherapiesforPPHNwere
aimed at lowering pulmonary vascular resistance and im-
proving mixing at the level of the atria and PDA. The
ventilator strategy used, is meant to reduce pulmonary
vascular resistance by improving oxygenation while aiming
for a pH of 7.4 and an arterial CO2 pressure (pCO2) between
4.0–5.5kPa. Ventilator settings were adjusted according
to the patient’s pulmonary condition, tidal volume, and
arterial blood gas determination. Patients received sedation
with morphine and, if necessary, neuromuscular blockade
with vecuronium. Inotropic agents (isoprenaline, dopamine,
dobutamine, and noradrenalin), and intravenous volume
replacement were used aggressively to maintain an adequate
arterial blood pressure. During iNOtherapy, nitric oxidewas
introduced into the inspiratory limb of the ventilator (5–
40ppm). In case of failure, intravenous vasodilators (tola-
zoline, epoprostenol, and enoximone) were started in the
absence of contraindications (hypotension, renal failure, and
haemorrhage) [1].
3.StatisticalAnalysis
Data analysis was performed using the SPSS software (ver-
sion 16; SPSS 2007, Chicago, Illinois, USA). Categori-
cal variables are presented as percentages and numbers.
Continuous variables were presented as means (standard
deviation) in normally distributed variables. Comparisons
between categorical variables were performed using χ 2 test
(independent variables), assessed in mortality and morbidity
to sex, severity of PPHN, pathophysiological mechanisms,Pulmonary Medicine 3
Table 1: Baseline characteristics of PPHN-patients.
N (%) All newborns (N = 143) GA ≥ 37 weeks (N = 91) GA < 37 weeks (N = 52)
Gender
Male 86 (60,1) 52 (57,1) 34 (65,4)
Use of iNO 95 (67,4) 65 (73) 30 (57,7)
Pathophysiology
Maladap/maldevelop 108 (75,5) 77 (84,6) 31 (59,6)∗
Underdevelopment 35 (24,5) 14 (15,4) 21 (40,4)∗
Severity PPHN
δ-SO2
Mild-moderate 81 (56,6) 43 (47,3) 38 (73,1)∗
Severe 62 (43,4) 48 (52,7) 14 (26,9)∗
Outcome
Overall mortality 51 (35.7) 26 (28.6) 25 (48.1)∗
PPHN-related mortality 45 (31.5) 23 (25.3) 22 (42.3)∗
GA = gestational age, iNO = inhaled nitric oxide, maladap = maladaptation, maldevelop = maldevelopment, statisticsigniﬁcance (P<. 05, ∗Chi square test).
use of inhaled nitric oxide and gestational age. Depending
on the type of variable, a Mann-Whitney U test, a Kruskal-
Wallis test, a Spearman’s rank correlation coeﬃcient, and
a T-test, one way Analysis of variance were used. In these
tests, a P-value less than .05 was considered signiﬁcant.
4.Results
143 patients with documented PPHN were enrolled in the
study. More than one third (36.4%) of the patients had
agestationalage(GA)lessthan<37weeks(deﬁnedasprema-
turity).In general,themajority ofpatientswere male,treated
with inhaled nitric oxide (iNO) and showed maladapta-
tion/maldevelopment as pathophysiological mechanism. In
the patient group with a GA < 37 weeks, signiﬁcantly more
children had mild-moderate PPHN, showed underdevelop-
ment as pathophysiological mechanism, and had a higher
mortality rate, either related to PPHN or not (Table 1).
The overall mortality in the patient cohort was high
(35.7%), and related to PPHN in more than 31% of the
patients.
Six children, 5 boys and one girl, died at a later stage, at
a mean age of3months (ranging from 10daysto6 months),
independent of PPHN. The reasons of death comprised
chronic lung disease, sepsis, cerebral haemorrhage, and
ventriculitis. Three children were premature born, two of
them suﬀered from mild-moderate PPHN (Table 2).
Considering the PPHN-related mortality, we did not
observe a diﬀerence in gender or severity of PPHN. Inhaled
nitric oxide was signiﬁcantly more used in term newborns
(≥37 weeks). A signiﬁcant majority of pathophysiological
underdevelopment was seen in the premature population
(<37 weeks), in contrast to the term newborns with sig-
niﬁcantmoremaladaptation/maldevelopment(Table 2).Sig-
niﬁcant correlations were seen between gestational age and
the use of iNO, as well as gestational age and type of
pathophysiologicalmechanism, also demonstrated by a mul-
tivariate analysis. In a logistic regression analysis Oxygen
Index (P = .02) and type of pathophysiological mechanism
(P ≤ .001) are independent predicting risk factors for
PPHN-related mortality in term newborns. No other risk-
factors for PPHN-related mortality could be identiﬁed by
multivariate analysis.
Between premature and term newborns, no diﬀerence
was observed in comorbidity or presenting symptoms, such
as asphyxia, infection, meconium aspiration, or congenital
anomalies, except for congenital heart disease (CHD). Four
term newborns were diagnosed simple transposition of the
great arteries (l-TGA), whereas no premature neonate had
aC H D .
5.Survivors
The remaining 92 patients (survivors) participated in the
cross-sectional observational study, with a mean followup
of 5.6 years (SD=3yrs),rangingfrom0to11years. T wo
patients were untraceable. Child Behaviour Checklists
(CBCLs)were sent to the 90survivors. The response rate was
61.1% (n = 55). Sixteen patients had a gestational age less
than 37 weeks, 39 patients more than 37 weeks. The mean
ageinresponders(4.89years,SD=2.62)issigniﬁcantlylower
than that in nonresponders (6.65 years, SD=3.19) (P<
.01). The severity of PPHN and type of pathophysiology
showed no signiﬁcant diﬀerences between responders and
nonresponders. All 55 responding families had the Dutch
nationality. Thirty-seven responding families represent male
patients (37/55, 67%). Only the data of the responders
were used for analysis. In 51 of the 55 patients, hospital
records and family doctor data (FD data) were available.
Basic characteristics of all surviving patients are shown in
Table 3.
6.Morbidity
The relation of PPHN to morbidity could be blurred by
coexisting diseases, sometimes directly related to therapy, as
in mechanical ventilation or maturation disorders in prema-
ture newborns. Therefore, only the data of term neonates,4 Pulmonary Medicine
Table 2: Patient characteristics of PPHN-related and non-PPHN-related mortality.
(a)
PPHN-related mortality (n)A l l n e w b o r n <37 weeks ≥37 weeks P-value
Total 45 22 23
Female 22 11 11
Inhaled NO 31 11 20 .03
Severity PPHN (δ-SO2)
Severe/severe + iNO 32/25 16/9 16/14
Mild-moderate/mild-mod + iNO 13/8 6/2 7/6
Severity (OI)
Mild <15 2
Moderate 15–25 2
Severe 25–40 5
Very severe >40 14 <.001
Pathophysiology
Maldevelop/maladap 20 5 15 .004
Maldevelop/maladap+ iNO 15 2 13 .001
Underdevelopment 25 17 8 .004
Underdevelopment + iNO 16 9 7
(b)
Non-PPHN-related morality
Patient Severity PPHN Pathophysiology Gestational age Cause of death iNO
(1)
￿ Severe Maladap/maldev 39+3 wks Chronic lung disease −
(2)
￿ Severe Maladap/maldev 29+3 wks Chronic lung disease −
(3)
￿ Severe Underdevelopment 40 wks Sepsis +
(4)
￿ Mild-moderate Maladap/maldev 38+6 wks Cerebral haemorrhage +
(5)
￿ Mild-moderate Maladap/maldev 29+6 wks Ventriculitis −
(6)
￿ Mild-moderate Underdevelopment 28+5 wks Chronic lung disease −
Maladap/maldev = maladaptation/maldevelopment,iNO = inhaled nitric oxide.
without syndromal anomalies, were evaluated, in order to
expel these coexisting symptoms. Basic characteristics are
shown in Table 4.
In the term newborns, more than one-third of the pa-
tientsfrequently use medication. Respiratory tract problems,
like asthma and pneumonia, is an important contributor of
morbidity, for which among others bronchodilators (n =
10) and inhaled steroids (n = 5) are used (Table 5).
Hearing impairment, mentioned by the parents, was seen
in ﬁve children (14.3%), somewhere in followup, with
permanent loss of high-frequency sound in two children and
combined permanent loss of high- and low-frequency sound
in one child. Nevertheless no patient is using a hearing aid.
Moreover, the medical records listed no hearing impairment.
Hearing impairment is seen in 3% of regular school going
children (age 4–18 years) in The Netherlands. Five children
(14.3%) have a visual impairment, that is, far-sightedness
(n = 2), myopia (n = 2), and strabismus (n = 1). Four
children have glasses/contact lenses. Visual impairment is
observedin2–6%oftheoverallDutchpaediatricpopulation.
For identifying the pathological role of PPHN on out-
come, an artiﬁcial division in preexisting disease (comor-
bidity categories: asphyxia, infection, MAS, CHD and the
combination of MAS, and infection) and morbidity (out-
come categories: respiration, CHD, major neurology and
visual and hearing impairment) was created. In a univariate
analysis of comorbidity categories and outcome categories,
we observed only a signiﬁcant correlation between the use of
iNO and respiratory complaints (Pearson correlation=0.65,
P = .03), suggesting a causal role for PPHN in outcome of
termpatients.However,thiscausal rolewasnot conﬁrmedin
a multivariate analysis and regression analysis of preexisting
disease and outcome (F = 5.8, P = .003).
7.ChildBehaviourSkills
In the analysis of child behaviour and social competency,
the results of the CBCL of PPHN survivors (n = 55),
reported by their parents, were used. In general, parents
asses their children as having an optimal behaviour in
85.7% (CBCL/1.5–5, 24/28 responders) and 81% (CBCL/6–
18, 17/21 responders), whereas in 14.3% (CBCL/1.5–5, 4/28
responders) and 19.1% (CBCL/6–18, 4/21 responders) the
child behaviour was scored as abnormal or at risk. Remark-
able is the large portion of abnormal social skills (57.9%,Pulmonary Medicine 5
Table 3: Patient characteristics of surviving patients.
Gestational Age (GA) <37 weeks ≥37 weeks P-value
Total 27 65
Female 6 29 .04
Inhaled NO 18 44
Severity PPHN
Severe 17 31
Severe (iNO) 11 21
Mild-moderate 10 34
Mild-moderate (iNO) 7 23
Severity (OI)
Mild <15 13
Moderate 15–25 17
Severe 25–40 18
Very severe >40 14∗
Pathophysiology
Maldevelop/maladap 22 60
Maldevelop/maladap+iNO 15 42
Underdevelopment 5 5
Underdevelopment + iNO 3 2
Comorbidity (n/%)
CHD (TGA) 1 14 .03
Asphyxia 2 10
Lunghypoplasia nos 4 0 .001
Lunghypoplasia (neuromuscular) 0 0
Lunghypoplasia (omphalocele) 0 0
Lunghypoplasia/CDH 0 5
Lunghypoplasia/cystic kidneys 1 0
Infection 5 11
Emphysema 1 0
Hydrops fetalis (unknown origin) 0 0
OI =oxygenindex,Maldevelop/maladap=maladevelopment/maladptation,
CHD = congenital heart disease.
11/19 responders) in children between 6 and 18 years. These
skills are not investigated in the CBCL/1.5–5 [8].
8.MaternalData
The overall mean age of mothers (n = 143) at delivery is
31 years (SD=4yrs), ranging from 21 to 43 years and did
not diﬀer from the average age of pregnant women in The
Netherlands of 30.7 years (2000) and 31.1 years (2006),
according to the Dutch Central Registration Agency(CBS).
Hospital records of the 55 responding mothers, demon-
strated six mothers with preexisting morbidity, such as sys-
temic hypertension, migraine, and diabetes. 15 mothers
experienced diseases during pregnancy, especially systemic
hypertension (n = 11), pre-eclampsia (n = 4), and gesta-
tional diabetes mellitus (n = 2). Complications were listed
in 22 pregnancies, such as premature rupture of membrane
(n = 5), premature contractions (n = 3), intrauterine
growth retardation (n = 2) and vaginal blood loss (n = 4)
with placental solution in two mothers.
Table 4: Patient characteristics of term surviving patients.
Surviving term responders n (%)
Total 35 (100%)
Female 18 (51.4%)
iNO 25 (71.4%)
Maladaptation/maldevelopment 35 (100%)
Severity PPHN
δ-SO2
Mild-moderate 18 (51.4%)
Severe 17 (48.6%)
Severity OI
Mild <15 5 (14.3%)
Moderate 15–25 10 (28.6%)
Severe 25–40 11 (31.4%)
Very severe >40 9 (25.7%)
ECMO 3 (8.6%)
HFOv 5 (14.3%)
Comorbidity
Asphyxia 8 (22.9%)
Infection 8 (22.9%)
MAS 10 (28.6%)
CHD 7 (20.4%)
Combination MAS/Asphyxia 2 (5.7%)
iNO = inhaled nitric oxide, OI = oxygen index, ECMO = extracorporeal
membrane oxygenation, MAS = meconium aspiration syndrome, CHD =
congenital heart disease, HFOv = high frequency oscillation ventilation.
Nineteen mothers used medication during pregnancy,
like antihypertensive agents (n = 4), insulin (n = 4),
antibiotics (n = 2), and iron replacement therapy (n = 3).
In contrast to earlier publications, no mother was using
a serotonin-reuptake inhibitor [11, 12].
9.Discussion
In this study we retrospectively investigated characteristics
of neonates suﬀering from PPHN, in tertiary cardiac and
neonatal intensive care unit. Subsequently, we studied the
health status of the survivors in this cohort, over an 11-year
period.
In our study cohort, more than one third of the patients
were premature newborns (GA < 37 weeks), taking into
account the incidence of prematurity in the general Dutch
population (7.8%, Perinatal Care 2003). The majority of
patientswere boys,were treated with iNO,and had maladap-
tation/maldevelopment as pathophysiological mechanism.
In the group of premature newborns with signiﬁcantly more
children with mild-moderate PPHN, we observed a higher
mortality rate, either related to PPHN or not, compared to
term newborns. Moreover, underdevelopmentas pathophys-
iological mechanism was seen signiﬁcantly more often in
premature babies. The overall mortality was high (Table 1),
though corresponding to the literature (11%, range 4–33%).
Focussing on term newborns, type of pathophysiological
mechanism (P<. 001) and Oxygen Index (P = .02) were the6 Pulmonary Medicine
Table 5: Morbidity status of term survivors.
Morbidity Medical data (n = 35) Questionnaires (n = 35) P-value
Medication use 12 (34.3%) 9 (25.7%)
Respiratory tract problems 10 (28.6%) 10 (28.6%)
Gastrointestinal tract problems 2 (5.8%) 3 (8.6%)
Congenital heart disease 7 (20%) 7 (20%)
Speech therapy 8 (22.9%) 12 (34.3%)
Physiotherapy 9 (25.7%) 14 (40%)
Delayed socioemotionaldevelopment 3 (8.6%) 0
Delayed mental development 7 (20%) 2 (5.8%)
Microcephaly 1 (2.9%) 1 (2.9%)
Seizures 1 (2.9%) 1 (2.9%)
Cerebral palsy 9 (25.7%) 9 (25.7%)
Tetraplegia 1 (2.9%) 1 (2.9%)
Hypotonia 2 (5.8%) 2 (5.8%)
Hearing impairment 0 5 (14.3%) .02
Visual impairment 5 (14.3%) 6 (17.1%)
Delayed motor development 14 (40%) 3 (8.6%) .002
only independent predicting risk factors for PPHN-related
mortality (regression analysis). We should make a comment
concerning the Oxygen Index in our term newborn popula-
tion, containing 14 children with a transposition of the great
arteries. In this congenital heart defect, the Oxygen Index,
does not represent a parameter for respiratory function, but
more a parameter for mixing of the blood pool and the
circulation. Taking this into account, the Oxygen Index
could be of more importance for the remaining term study
population.
In the literature, concerning outcome and health-status
of PPHN patients, we can distinguish two episodes, namely,
the publications originating from the preinhaled nitric oxide
era (pre-NO-era), and the literature from the inhaled nitric
oxide era (NO-era) [3–7, 13]. In the pre-NO-era Ballard
reviewed the current literature at that time, concerning the
eﬀect of hyperventilation in PPHN patients, focussed on
mental and psychomotor development. Thirty-six patients,
coming from three studies (Breet (1981), Bernbaum (1981)
and Ferrara (1983)), showed, in a followup ranging from 12
to 35 months, normal neurological outcome in 32 patients,
scoredby MentalDevelopmentIndex(MDI)and Psychomo-
tor Development Index (PDI), both as part of the Bayley
assessment (ﬁrst edition). In their own cohort Ballard stud-
ied 11 patients, all term babies, 9 patients were evaluated at
the age of 2 years, with normal neurological outcome in 8
patients[13].One childhad some delays inﬁne motordevel-
opment. Leavitt and coworkers looked, in the pre-NO era,
at 12 patients, all term- or near-term neonates with PPHN,
who were on mechanical ventilation at least 72 hours, with
a mean age at followup of 20 months, ranging from 12 to 26
months. Neurodevelopmentexamination, Bayleyassessment
included, and visually reinforced audiometry (VRA) were
performed. Four children showed abnormal neurodevelop-
ment, including three children with sensorineurinal hearing
impairment [5]. From the NO era, we considered three
studies by Ichiba et al., Lipkin et al., and Ellington et al. as
relevant in the comparison to our study [3, 4, 6]. Ichiba et
al. investigated 18 term and near-term neonates with PPHN
treated with iNO (≥34 weeks gestational age). They divided
their patients into three groups on the basis of response to
iNO, namely, early response in 8 patients, late response in
8 patients, and poor response in 8 patients. The mortality
rate was 16.7%; all patients belonged to the poor response
group. The initial dose of iNO was 10 parts per million
(ppm), if needed increased to 40ppm. Followup, at three
years, showed reactive airway disease in 5 patients, no loss
of sensorineurinal hearing and a signiﬁcant higher incidence
of normal neurodevelopment outcome in the early response
group, however only one patient was identiﬁed as having
a mild neurodevelopment disability [4]. In the study of
Lipkin 155 term neonates (GA ≥ 37 weeks) were checked,
at the age of one year. Patients were divided in two groups
(iNO versus placebo). In 144 patients surviving patients,
the second Bayley Scales of Infant Development (second
edition), neurological examination, sound ﬁeld audiometry,
and tympanometry were performed. No signiﬁcant diﬀer-
ences between the placebo and iNO groups were seen in
any long-term outcome. There were major neurological
abnormalities in 13%, cognitive delays in 30%, and hearing
loss in 19% of the infants. Apart from the short follow-up
period, patients with lunghypoplasia syndromes, chromoso-
mal abnormalities, intracranial haemorrhage (≥grade 2), or
patients treated with surfactant or high frequency oscillation
ventilation were excluded [6]. Finally Ellington et al. looked
at 60 patients, surviving PPHN, with a follow-up interval
ranging from 1 to 4 years. The gestational age ranged from
34 to 43 weeks. Parents were interviewed by telephone, using
a trained interviewer and standardized instruments. The
overall neurological handicap rate was 15%, a hearing deﬁcit
i n7 % ,a n db e h a v i o u r a lp r o b l e m si n2 6 % .N oa d v e r s eh e a l t h
or neurodevelopment outcomes have been observed amongPulmonary Medicine 7
infants treated with nitric oxide for PPHN, as later reported
by Ellington et al. [3] and Konduri and coworkers [14].
The relation of PPHN to morbidity could be blurred by
coexisting diseases. Therefore, only the data of term neo-
nates, without syndromal anomalies, were evaluated, trying
to expel these coexisting symptoms. In our term responding
newborns with PPHN, respiratory problems (34.3%; 12/35)
were frequently seen, in comparison to the prevalence of
asthma, chronic bronchitis, and emphysema in 10% of the
Dutch children between 4 and 12 years of age (according to
the CBS, Dutch Central Registration Agency 2008). Seven
preterm children suﬀered from chronic lung disease (43.8%;
7/16), for which a daily need of bronchodilators existed.
A high prevalence of visual impairment of 14.3% (5/35)
was observed, in contrast to the 2–6% in the general Dutch
children population. Though, a signiﬁcant relation between
visual impairment and PPHN could not be demonstrated
in our cohort. Hearing impairment in our study comprises
14.3%(5/35)ofthe children, obtained by the questionnaires,
remarkably not conﬁrmed by the medical records or family
doctordata. In two of the 5 patients, the hearing impairment
is permanent, although no patient is using a hearing aid.
The incidenceofhearing impairment, observedbytheDutch
school doctors,in childrenbetween 4and 18yearsis3%.The
majority of these hearing complaints are temporarily, often
due to ear infections. The literature mentions various ﬁgures
of incidence, ranging from 0 to 52.5% [3, 4, 6, 15–17].
The prevalence of impaired motor development, caused
by delayed motor development (40%) and cerebral palsy
(25.7%) is comparable to the results in early reports, con-
cerningPPHN(15–33%),howeverbeinghighincomparison
to the general Dutch children population (<1%). Further-
more, Boys showed signiﬁcant more delayed neuromotor
developmentthan girls, corresponding with results in earlier
reports.
In a univariate analysis of comorbidity categories and
outcome categories, we observed only a signiﬁcant corre-
lation between the use of iNO and respiratory complaints
(Pearsoncorrelation=0.65,P = .03),suggestinga causalrole
for PPHN in outcome of term patients. However, this causal
role was not conﬁrmed in a multivariate analysis and regres-
sion analysis of preexisting disease and outcome (F = 5.8,
P = .003), suggesting no additional causal role of PPHN in
outcome of term newborns.
Using the results of the CBCL, we ﬁrst should acknowl-
edge its highly subjective nature. However, we registered
an incidence of 4.1% (2/49) of abnormal behaviour and
12.2% (6/49) of the children show behaviour at risk. These
results correspond with the general prevalence of 5–15% of
Dutch children with mild-to-moderate behavioural prob-
lems. In contrast, Ellington and coworkers observed signif-
icant behavioural problemsin 26% of the children, surviving
PPHN. In their study, the follow-up interval was limited,
ranging from 1 to 4 years, whereas the gestational age
ranged from 34 to 43 weeks. Parents were interviewed by
telephone, using a trained interviewer and standardized
instruments [3]. The CBCL provides information concern-
ing socioemotional performance/skills of children, scored in
the complete paediatric population, only possible to test
in older children (CBCL/6–18). We were able to obtain
these scores in 19 patients, which showed a distinct high
proportion of abnormal skills in 57.9% (n = 11).
Considering our methodology, we were faced with lim-
itations. The lack of a case-matched study population forces
us to compare patients and their morbidity and behavioural
skills with children out of the general dutch population,
measured by national health registries, such as PGO, a
Dutch program of Preventive Healthcare Statistics, CBS,
the Dutch Central Registration Agency and Prenatal Care,
a register for neonatal health aspects. Secondly, the use of
questionnaires could lead to a response bias. We noticed
as i g n i ﬁ c a n td i ﬀerence in age of responders, as well as the
factthatallrespondershavingtheDutchnationality.Parental
remembrance and response could be higher in younger
patients and in cases with a more severe clinical course,
although, in retrospect, no signiﬁcant diﬀerences in severity
and type of pathophysiological mechanism were observed
between responders and nonresponders.
10.Conclusion
In this combined retrospective and prospective cross-
sectional observational study143consecutivenewbornswith
PPHN were studied over an 11-year period. In contrast to
early publications, we experienced a large contribution of
premature neonates. In our series, PPHN was a serious
and often fatal condition, associated with a high mortality
(31.5%) and morbidity (64.7%). Above all the application
of inhaled nitric oxide did not improve the mortality rate or
morbidity. Mortality was correlated with the pathophysiol-
ogy (P<. 01) and severity (P = .05) of PPHN. Morbidity
ﬁgures in survivors (response rate 61.1%) revealed a long-
term morbidity during followup, represented by respiratory
problems, delayed/impaired motor development, cerebral
palsy, and vision impairment. The use of medication is high,
as well as the appealing for health care. However, in term
newborns, the pathological role of PPHN on morbidity,
could not be proven. Outcome and morbidity was directly
related to the preexisting disease.
Further study, preferably a matched-control prospective
study with physical examination and observation, is needed
to explore diﬀerentaspects ofmorbidity inrelation to PPHN
more thoroughly.
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